REFERENCE: Abstract V-1385, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007 JUAN BERENGUER, Hospital Gregorio Marañón, Madrid
A retrospective study has thrown doubt on the theory that protease inhibitors (PIs) are a preferable antiretroviral treatment for patients co-infected with HIV and Hepatitis C virus. Previous research had suggested that PIs had a more beneficial effect on liver fibrosis than NNRTIs, but a study based at the Hospital Gregorio Marañón in Madrid has found the opposite. Derek Thorne discussed the data with Juan Berenguer.
Mitchell Shiffman
REFERENCE: N Engl J Med 2007;357:124-34
MITCHELL SHIFFMAN, Virginia Commonwealth University, Richmond
Standard anti-viral therapy for Hepatitis
CHLOE THIO, Johns Hopkins University School of Medicine
REFERENCE: Abstract: 136LB, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February
[...] post by admin delivered by Medtrials and [...]
[...] post by admin delivered by Medtrials and [...]